Yann Mazabraud Net Worth

The estimated Net Worth of Yann Mazabraud is at least $3.07 Milion dollars as of 14 April 2024. Mr Mazabraud owns over 10,375 units of Rhythm Pharmaceuticals stock worth over $1,719,440 and over the last 5 years he sold RYTM stock worth over $659,334. In addition, he makes $693,616 as Exec. VP & Head of International at Rhythm Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Mazabraud RYTM stock SEC Form 4 insiders trading

Mr has made over 7 trades of the Rhythm Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,375 units of RYTM stock worth $511,591 on 14 April 2024.

The largest trade he's ever made was selling 16,000 units of Rhythm Pharmaceuticals stock on 19 March 2024 worth over $627,520. On average, Mr trades about 2,701 units every 53 days since 2019. As of 14 April 2024 he still owns at least 34,870 units of Rhythm Pharmaceuticals stock.

You can see the complete history of Mr Mazabraud stock trades at the bottom of the page.

Mr. Yann Mazabraud biography

Yann Mazabraud is the Exec. VP & Head of International at Rhythm Pharmaceuticals.

What is the salary of Mr Mazabraud?

As the Exec. VP & Head of International of Rhythm Pharmaceuticals, the total compensation of Mr Mazabraud at Rhythm Pharmaceuticals is $693,616. There are 2 executives at Rhythm Pharmaceuticals getting paid more, with Hunter Smith having the highest compensation of $1,922,850.

How old is Mr Mazabraud?

Mr Mazabraud is 48, he's been the Exec. VP & Head of International of Rhythm Pharmaceuticals since . There are 12 older and 5 younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals Inc. is Dr. David P. Meeker M.D., 67, who is the Chairman, Pres & CEO.

What's Mr Mazabraud's mailing address?

Yann's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.

Insiders trading at Rhythm Pharmaceuticals

Over the last 13 years, insiders at Rhythm Pharmaceuticals have traded over $83,445,563 worth of Rhythm Pharmaceuticals stock and bought 6,290,000 units worth $106,961,700 . The most active insiders traders include Forest Baskett, Scott D Sandell a Peter J Barris. On average, Rhythm Pharmaceuticals executives and independent directors trade stock every 17 days with the average trade being worth of $3,358,405. The most recent stock trade was executed by Pamela J. Cramer on 9 September 2024, trading 4,099 units of RYTM stock currently worth $77,963.

What does Rhythm Pharmaceuticals do?

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.

Complete history of Mr Mazabraud stock trades at Rhythm Pharmaceuticals a Trevi Therapeutics

Rhythm Pharmaceuticals executives and stock owners

Rhythm Pharmaceuticals executives and other stock owners filed with the SEC include:

• Hunter Smith,
  Chief Financial Officer
• Dr. David P. Meeker M.D.,
  Chairman, Pres & CEO
• Yann Mazabraud,
  Exec. VP & Head of International
• Hunter C. Smith M.B.A.,
  CFO & Treasurer
• Hunter C. Smith,
  CFO, Treasurer & Sec.
• Jennifer L. Chien,
  Exec. VP & Head of North America
• Joseph Shulman,
  Chief Technical Officer
• Jennifer Good,
  Independent Director
• Stuart Arbuckle,
  Independent Director
• David Meeker,
  Chairman of the Board, President, Chief Executive Officer
• David McGirr,
  Independent Director
• Christophe Jean,
  Independent Director
• Todd Foley,
  Independent Director
• Edward Mathers,
  Independent Director
• Dr. David P. Meeker,
  Chairman, Pres & CEO
• Yann Mazabraud,
  Executive Vice President, Head of International
• Hannah Deresiewicz,
  IR Contact Officer
• Pamela Cramer,
  Chief HR Officer
• Sarah Ryan,
  VP of Sales & Marketing
• William T. Roberts,
  Chief Accounting Officer
• Dr. Alastair Garfield Ph.D.,
  VP & Head of Research
• Dr. Murray W. Stewart M.D.,
  Chief Medical Officer
• Simon D. Kelner,
  Chief HR Officer
• Satej Bhandarkar,
  Sr. VP of Program Management, Strategy & Corp. Devel.
• Jim Flaherty,
  Sr. VP & Gen. Counsel
• David Connolly,
  Head of Investor Relations & Corp. Communications
• Rock Ventures Lp Third Rock...,
  
• Fred T. Fiedorek,
  Chief Medical Officer
• Nithya Desikan,
  Chief Commercial Officer
• Der Ploeg Leonardus H.T. Van,
  Chief Scientific Officer
• Neil Exter,
  Director
• Rock Ventures Lp Third Rock...,
  
• Bioventures V, L.P.Evnin Lu...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 13 Lp...,
  
• Inc Pfizer,
  10% owner
• S.A. Ipsen,,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Jonathan Silverstein,
  Director
• Harbor Master Investors (Ca...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Bros. Advisors Lp Baker Bro...,
  
• Simon Kelner,
  Chief Human Resources Officer
• Murray Stewart,
  Chief Medical Officer
• Advisors Llc Orbi Med Capit...,
  
• William T. Roberts,
  Chief Accounting Officer
• Keith Michael Gottesdiener,
  CEO & President
• Capital Management, L.P.Ra ...,
  
• Jennifer Kayden Lee,
  EVP, Head of North America
• Joseph Shulman,
  Chief Technical Officer
• Lynn A. Tetrault,
  Director
• Pamela J. Cramer,
  Chief Human Resources Officer
• Linda Shapiro Manning,
  Chief Medical Officer
• Christopher Paul German,
  Corporate Controller & CAO
• Alastair Garfield,
  Chief Scientific Officer